News & Analysis as of

Securities Transactions Private Equity

Stikeman Elliott LLP

Ten LPs + 85 Investors Over Four Years = Unlicensed Trading Allegation from the OSC

Stikeman Elliott LLP on

One of the grey areas for real estate development, private equity and venture capital firms (“sponsors”) that serially launch new funds is how frequently a sponsor can come to market with a new fund offering without hitting...more

Nelson Mullins Riley & Scarborough LLP

The United States Second Circuit Court of Appeals' Decision in Kirschner v. JP Morgan

In the ruling decided by the United States Second Circuit Court of Appeals on Aug. 24 in Kirschner v. JP Morgan, the court upheld the District Court’s decision stating that the origination and distribution of $1.8B in...more

Proskauer Rose LLP

Preferred Equity PIPEs Provide Flexibility in the Age of COVID-19

Proskauer Rose LLP on

PIPEs (private investments in public equity) provide investors and public companies with a flexible vehicle for bespoke capital solutions that can be executed quickly in the volatile markets that have arisen in the COVID-19...more

McDermott Will & Emery

[Webinar] PEER Series - What Private Equity Wants to Know About PIPEs - August 20th, 1:00 pm - 1:45 pm ET

McDermott Will & Emery on

As recent volatile markets have necessitated diversification in transaction and financing structures, private investment in public equity (PIPE) transactions have been on the rise, with sponsors increasingly considering these...more

McDermott Will & Emery

[Webinar] The Explosion of SPACs – What Private Equity Wants to Know - August 6th, 1:30 pm - 2:15 pm EDT

McDermott Will & Emery on

The interest in special purpose acquisition company (SPAC) transactions continues to skyrocket, with nearly half of all IPOs year-to-date filed by SPACs and with “de-SPAC” transactions increasing. Join McDermott on...more

Arnall Golden Gregory LLP

[Webinar] Money, Money, Money: Raising Capital and Exit Transactions for Life Sciences Companies - October 3rd, 12:00 pm ET

Access to capital is critical for life sciences companies. Securing funding can be a lengthy and complex process compounded by the need to plan for various exit transaction scenarios. Register now for this one-hour,...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide